Susan Bobulsky, Chief Commercial Officer, MRD at Adaptive Biotechnologies Corp.. Biography, career history and compensation sourced from SEC proxy filings.
About
Susan Bobulsky has served as Adaptive Biotechnologies' Chief Commercial Officer, MRD since January 2024, leading the commercial organization for the clonoSEQ minimal residual disease franchise. She served in commercial and strategic planning roles of ascending responsibility after joining Adaptive in September 2014. Before Adaptive she spent nine years as an Associate Principal with ZS Associates, a healthcare management consulting firm, specializing in commercialization strategy and execution for therapeutic and diagnostic products. Ms. Bobulsky holds an MBA from the Stanford Graduate School of Business and a BS in Science, Technology and Society from Stanford University.
Roles
Adaptive Biotechnologies Corp.
Chief Commercial Officer, MRD · Current role
January 2024–present
Adaptive Biotechnologies
Chief Commercial Officer, MRD
January 2024 - present
Adaptive Biotechnologies
Commercial and strategic planning roles
September 2014 - January 2024
ZS Associates
Associate Principal · Nine years in commercialization strategy for therapeutic and diagnostic products
2005 - 2014
Fixed Compensation
FY 2025
Salary
$435,750
ComponentAnnual base salary earned in FY2025
All other compensation
$4,480
Component401(k) matching contributions and related benefits
Total compensation
$3,547,558
Performance Compensation
Data from FY 2025
Cash incentive
Non-equity incentive plan compensation
$226,013
Target Opportunity
—
PlanAnnual cash incentive tied to corporate and individual goals for 2025
Stock awards
Stock awards
$1,883,990
FormRSUs and performance stock units (rTSR-based), ASC 718 grant-date fair value
Option awards
$997,325
FormOne-time PSU/option award, ASC 718 grant-date fair value